Kaitlin R. Sprouse

This study determines the structure of the 2026 Bundibugyo virus glycoprotein and identifies conserved epitopes for antibody therapeutics and pan-ebolavirus vaccines.

This paper computationally designs thermostable miniproteins that neutralize Nipah and Hendra viruses with subnanomolar affinity and potent in vitro antiviral activity.

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

This paper develops a stabilized MERS-CoV spike ferritin nanoparticle vaccine that elicits strong neutralizing antibodies in mice and non-human primates, providing protection against MERS-CoV infection.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

This study maps immunodominant sites on MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans, showing peak neutralizing activity against S1 and RBD epitopes.

This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

The paper introduces a thermodynamically coupled biosensor to rapidly detect neutralizing antibodies against SARS-CoV-2 strains in serum samples.